Adverse events and stroke prevention by interventional left atrial appendage occlusion in patients with low CHA
LAA closure
atrial fibrillation
bleeding risk
cardiac intervention
ischemic stroke
procedural complications
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
11
2021
accepted:
13
03
2022
pubmed:
7
4
2022
medline:
10
6
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Interventional left atrial appendage occlusion (LAAO) is routinely performed in patients with nonvalvular atrial fibrillation and contraindications to standard anticoagulation. We investigated its role in patients at low stroke risk, and compared the effectiveness and safety in patients with low versus high risk. LAARGE is a prospective registry depicting the clinical reality of LAAO. LAAO was conducted with different standard commercial devices, and follow-up period was 1 year. Patients with started procedure and documented CHA A total of 638 patients from 38 centers were divided into CHA Low-risk patients had no nonfatal strokes and major bleedings within 1 year after hospital discharge but had unexpectedly high rates of moderate procedural complications. The indication in these patients should be strictly defined based on an individual benefit-risk assessment.
Sections du résumé
BACKGROUND
Interventional left atrial appendage occlusion (LAAO) is routinely performed in patients with nonvalvular atrial fibrillation and contraindications to standard anticoagulation.
AIMS
We investigated its role in patients at low stroke risk, and compared the effectiveness and safety in patients with low versus high risk.
METHODS
LAARGE is a prospective registry depicting the clinical reality of LAAO. LAAO was conducted with different standard commercial devices, and follow-up period was 1 year. Patients with started procedure and documented CHA
RESULTS
A total of 638 patients from 38 centers were divided into CHA
CONCLUSIONS
Low-risk patients had no nonfatal strokes and major bleedings within 1 year after hospital discharge but had unexpectedly high rates of moderate procedural complications. The indication in these patients should be strictly defined based on an individual benefit-risk assessment.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2064-2070Subventions
Organisme : Stiftung Institut für Herzinfarktforschung, Ludwigshafen am Rhein, Germany
Informations de copyright
© 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(5):373-498.
Ceornodolea AD, Bal R, Severens JL. Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries. Stroke Res Treat. 2017;2017:8593207.
Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update. Europace. 2019:euz258.
Fastner C, Hoffmann L, Aboukoura M, et al. Real-world experience comparing two common left atrial appendage closure devices. BMC Cardiovasc Disord. 2018;18(1):171.
Fastner C, Nienaber CA, Park JW, et al. Impact of left atrial appendage morphology on indication and procedural outcome after interventional occlusion: results from the prospective multicentre German LAARGE registry. EuroIntervention. 2018;14(2):151-157.
Kim YG, Shim J, Oh SK, Lee KN, Choi JI, Kim YH. Electrical isolation of the left atrial appendage increases the risk of ischemic stroke and transient ischemic attack regardless of postisolation flow velocity. Heart Rhythm. 2018;15(12):1746-1753.
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.
Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.
Brachmann J, Lewalter T, Akin I, et al. Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE Registry. J Interv Card Electrophysiol. 2020;58(3):273-280.
Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace. 2014;16(10):1397-1416.
Fastner C, Brachmann J, Lewalter T, et al. Left atrial appendage closure in patients with a reduced left ventricular ejection fraction: results from the multicenter German LAARGE registry. Clin Res Cardiol. 2020;109:1333-1341.
Fastner C, Brachmann J, Lewalter T, et al. Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry. Clin Res Cardiol. 2020;109:1333-1341.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510.
Li YG, Lip GYH. Stroke prevention in atrial fibrillation: state of the art. Int J Cardiol. 2019;287:201-209.
Verbrugge FH, Martin AC, Siegal D, et al. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. Heart. 2020;106(11):845-851.
Micieli A, Wijeysundera HC, Qiu F, Atzema CL, Singh SM. A decision analysis of percutaneous left atrial appendage occlusion relative to novel and traditional oral anticoagulation for stroke prevention in patients with new-onset atrial fibrillation. Med Decis Making. 2016;36(3):366-374.
Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11(10):1170-1179.
Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302-1308.
Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122-3135.
Cetin M, Cakici M, Zencir C, et al. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113(6):950-956.
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.